Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. [PDF]
, 2019 Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs)
Beck, Kristen M +4 more
core
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]
, 2017 Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman +25 more
core +3 more sources
Identification of novel small molecule inhibitors of ETS transcription factors
FEBS Letters, EarlyView.ETS transcription factors play an essential role in tumourigenesis and are indispensable for sprouting angiogenesis, a hallmark of cancer, which fuels tumour expansion and dissemination. Thus, targeting ETS transcription factor function could represent an effective, multifaceted strategy to block tumour growth. The evolutionarily conserved E‐Twenty‐Six
Shaima Abdalla +9 more
wiley +1 more source
A scoping review of patient selection methods for proton therapy
Journal of Medical Radiation Sciences, 2022 The aim was to explore various national and international clinical decision‐making tools and dose comparison methods used for selecting cancer patients for proton versus X‐ray radiation therapy.
Nicole Zientara +3 more
doaj +1 more source
An ensemble of machine learning and anti-learning methods for predicting tumour patient survival rates [PDF]
, 2016 This paper primarily addresses a dataset relating to cellular, chemical and physical conditions of patients gathered at the time they are operated upon to remove colorectal tumours. This data provides a unique insight into the biochemical and immunological status of patients at the point of tumour removal along with information about tumour ...
arxiv +1 more source
Prostate embolization: patient selection, clinical management and results
CVIR Endovascular, 2019 BackgroundProstate artery embolization is an emerging technique, that with the continued publication of promising data, is slowly moving from the research to the everyday clinical setting.Main bodyThis paper reviews the patient selection, clinical ...
S. Young, J. Golzarian
semanticscholar +1 more source
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations. [PDF]
, 2017 Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel.
Hoffman-Censits, Jean, Patel, Sheel
core +3 more sources
miRNA‐29 regulates epidermal and mesenchymal functions in skin repair
FEBS Letters, EarlyView.miRNA‐29 inhibits cell‐to‐cell and cell‐to‐matrix adhesion by silencing mRNA targets. Adhesion is controlled by complex interactions between many types of molecules coded by mRNAs. This is crucial for keeping together the layers of the skin and for regenerating the skin after wounding.
Lalitha Thiagarajan +10 more
wiley +1 more source
The optimal treatment of multivessel coronary artery disease [PDF]
, 2014 The practice of percutaneous coronary intervention has overtaken coronary bypass surgery in the treatment of ischaemic heart disease. Several randomized controlled as well as registry and observational trials have addressed the issue of patient selection
Manche, Alexander
core
First report of multi-drug resistant tuberculosis in a systemic lupus erythematosus patient. [PDF]
, 2015 BackgroundTreatment of a multi-drug resistant tuberculosis (MDR-TB) patient is clinically challenging, requiring a minimum of 18 months of therapy. Its occurrence in a systemic lupus erythromatosus (SLE) patient may complicate management of both MDR-TB ...
Dierberg, Kerry L +3 more
core +1 more source